Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mometasone
Drug ID BADD_D01490
Description Mometasone is a corticosteroid not currently used in medical products. [Mometasone furoate] however, is still in use.
Indications and Usage The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.
Marketing Status experimental
ATC Code D07AC13; D07XC03; R01AD09; R03BA07
DrugBank ID DB00764
KEGG ID D08227
MeSH ID D000068656
PubChem ID 441335
TTD Drug ID D03HYX
NDC Product Code 65162-891; 69238-2446
UNII 8HR4QJ6DW8
Synonyms Mometasone Furoate | Furoate, Mometasone | Nasonex | Mometasone Furoate Monohydrate | Furoate Monohydrate, Mometasone | Monohydrate, Mometasone Furoate | Asmanex Twisthaler | Twisthaler, Asmanex | Asmanex | Rinelon | Elocon | Sch 32088 | Sch-32088 | Sch32088 | Mometasone
Chemical Information
Molecular Formula C22H28Cl2O4
CAS Registry Number 105102-22-5
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual impairment06.02.10.0130.000332%-
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Hypoacusis04.02.01.0060.000089%
Seasonal allergy06.04.01.013; 10.01.04.001; 22.04.04.0080.000404%-
Contusion12.01.06.001; 15.03.05.007; 23.03.11.002; 24.07.06.001--
Rhinalgia22.12.03.0200.000303%-
Large intestine polyp07.20.01.010; 16.05.02.006---
Ear discomfort04.03.01.0050.000404%-
Eye pruritus06.04.05.0060.000303%-
Respiratory tract congestion22.02.07.0030.000202%-
Nasal discomfort22.12.03.0120.001674%-
Skin bacterial infection11.02.01.007; 23.11.02.017---
Musculoskeletal discomfort15.03.04.001---
Type IV hypersensitivity reaction10.01.03.022---
Restless legs syndrome15.05.03.012; 17.02.07.0080.000202%-
Adverse event08.06.01.0100.000736%-
Bacterial infection11.02.01.005---
Biliary tract disorder09.02.03.0010.000059%-
Mediastinal disorder22.09.03.001---
Abnormal behaviour19.01.01.0010.000059%-
Decreased appetite08.01.09.028; 14.03.01.005--
Nasal disorder22.04.03.0040.000433%-
Sinus disorder22.04.06.0020.000766%
Poor quality sleep17.15.04.002; 19.02.05.0050.000303%-
Increased upper airway secretion22.12.03.0070.000303%-
Oropharyngeal discomfort07.05.05.008; 22.12.03.0150.000160%-
Oropharyngeal pain07.05.05.004; 22.12.03.0160.000504%
Upper-airway cough syndrome22.12.03.0360.000706%
Foetal growth restriction18.03.01.0020.000059%
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene